TABLE 2.
Study name | Total N | PD‐L1 level (experiment/control) | Age (median) (experiment/Control) | Male (n,%) (experiment/control) | ||
---|---|---|---|---|---|---|
≥50% | 1%–50% | ≤1% | ||||
Checkmate 026 | 541 | 88/126 | 208/210 | 0 | 63.0/65.0 | 184(67.9)/148(54.8) |
Keynote 189 | 616 | 132/70 | 128/58 | 127/63 | 65.0/63.5 | 254(62.0)/109(52.9) |
Keynote 407 | 559 | 73/73 | 103/104 | 95/99 | 65.5/65.0 | 220(79.1)/235(83.6) |
Checkmate 227 | 1739 | 205/214/192 (Nivo+Ipi/Nivo/Chemo) | 191/182/205 (Nivo+Ipi/Nivo/Chemo) | 187/177/186 (Nivo+Ipi/Nivo+Chemo/Chemo) |
64.0/64.0/64.0 (Nivo+Ipili/Nivo/Chemo) 63.0/64.0/64.0 (Nivo+Ipi/Nivo+Chemo/Chemo) |
255 (64.4)/272 (68.7)/260 (65.5) (Nivo+Ipili/Nivo/Chemo) 138(73.8)/130(73.4)/125(67.2) (Nivo+Ipili/Nivo+Chemo/Chemo) |
IMpower 130 | 679 | 88/42 | 128/65 | 235/121 | 64.0/65.0 | 266(59.0)/134(58.8) |
IMpower 131 | 683 | 47/44 | 136/125 | 160/171 | 65.5/65.0 | 279(81.0)/278(82.0) |
IMpower 132 | 578 | 25/20 | 63/73 | 88/75 | 64.0/63.0 | 192(65.8)/192(67.1) |
Keynote 021G | 123 | 20/17 | 19/23 | 21/23 | 62.5/63.2 | 22(37.0)/26(41.0) |
Keynote 024 | 305 | 125/124 | 0 | 0 | 64.5/66.0 | 92(59.7)/95(62.9) |
Keynote 042 | 1273 | 299/300 | 338/337 | 0 | 63.0/63.0 | 450(70.6)/452(71.0) |
MYSTIC | 1092 | 118/108/107 (Durva/Durva+Treme/Chemo) | NA | 95/76/83 (Durva/Durva+Treme/Chemo) | 64.0/65.0/64.5 | 113 (69.3) /118 (72.4) /106 (65.4) |
IMpower 110 | 554 | 107/98 | 170/179 | 0 | 64.0/65.0 | 196(70.8)/196(69.7) |
Camel | 412 | 49/69 | 108/97 | 30/20 | 59.0/61.0 | 146(71.2)/149(72) |
Study name | Nonsquamous (n,%)(Experiment/Control) | Never Smoked (n,%)(Experiment/Control) | ECOG 0(n,%) | CNS metastasis (n,%) | Asia | |
---|---|---|---|---|---|---|
Checkmate 026 | 205 (76)/206(76) | 30 (11)/29 (11) | 85 (31)/93 (34) | 33 (12)/36 (13) | 30(11)/17 (6.3) | |
Keynote 189 | 410 (100)/206(100) | 48 (11.7)/25 (12.1) | 186 (45.4)/80 (38.8) | 73 (17.8)/35 (17) | 4 (1)/6 (2.9) | |
Keynote 407 | 0/0 | 22 (7.9)/19 (6.8) | 73 (26.3)/90 (32.0) | 20 (7.2)/24 (8.5) | 54 (19.4)/52 (18.5) | |
Checkmate 227 |
279 (70.5)/279 (70.5)/281 (70.8) (Nivo+Ipi/Nivo/Chemo) 140 (74.9)/134 (75.7)/140 (75.3) (Nivo+Ipi/Nivo+Chemo/Chemo) |
56 (14.1)/50 (12.6)/51 (12.8) (Nivo+Ipi/Nivo/Chemo) 23 (12.3)/27 (15.3)/27 (14.5) (Nivo+Ipi/Nivo+Chemo/Chemo) |
135 (34.1)/142 (35.9)/134 (33.8) (Nivo+Ipi/Nivo/Chemo) 69 (36.9)/59 (33.3)/57 (30.6) (Nivo+Ipi/Nivo+Chemo/Chemo) |
41 (10.4)/42 (10.6)/40 (10.1) (Nivo+Ipi/Nivo/Chemo) 23 (12.3)/16 (9.0)/11 (5.9) (Nivo+Ipi/Nivo+Chemo/ Chemo) |
81 (20.5)/66 (16.7)/81 (20.4) (Nivo+Ipi/Nivo/Chemo) 40 (21.4)/36 (20.3)/43 (23.1) (Nivo+Ipi/Nivo+Chemo/Chemo) |
|
IMpower 130 | 451 (100)/228 (100) | 48 (11)/17(7) | 189 (42%)/91 (40%) | NG | 12 (3)/3(1) | |
IMpower 131 | 0/0 | 32 (9.3)/23(6.8) | 115 (33.5)/110 (32.4) | NG | 41 (12.0)/37 (10.9) | |
IMpower 132 | 292 (100)/286 (100) | 37 (12.7)/30(10.5) | 126 (43)/114 (40) | NG | 71 (24.3)/65 (22.7) | |
Keynote 021G | 60 (100)/63 (100) | 15 (25)/9(14) | 24 (40) /29 (46) | 9 (15)/6 (10) | 5 (8)/5 (8) | |
Keynote 024 | 125 (81.2)/124 (82.1) | 5 (3.2) /19(12.6) | 54 (35.1)/53 (35.1) | 18 (11.7)/10 (6.6) | 21(13.6) 19 (12.6) | |
Keynote 042 | 394 (62)/388(61) | 142 (22)/140 (22) | 198 (31)/192 (30) | 35 (5)/35 (5) | 85 (29)/185 (29) | |
MYSTIC |
111 (68.1)/ 110 (67.5)/110 (67.9) (Durva/Durva+Treme/Chemo) |
24 (14.7)/ 25 (15.3)/21 (13.0) (Durva/Durva+Treme/Chemo) |
57 (35.0)/65 (39.9)/70 (43.2) (Durva/Durva+Treme/Chemo) |
NG |
59 (36.2)/50 (30.7) /47 (29.0) (Durva/Durva+Treme/Chemo) |
|
IMpower 110 | 277 (100)/277 (100) | 37 (13.4)/35 (12.6) | 97 (35.0)/102 (36.8) | NG | 45 (16.2)/30 (10.8) | |
Camel | 205 (100)/207 (100) | NA/NA | 48 (23.4)/36 (17.5) | 10 (5)/5 (2) | NG |
Abbreviations: Camre, camrelizumab; Chemo, chemotherapy; Durva, durvalumab; Ipi, ipilimumab; Nivo, nivolumab; Treme, tremelimumab.